Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy have transformed the treatment of estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. However, some patients do not respond to this treatment, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Main, Sasha C., Cescon, David W., Bratman, Scott V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511796/
https://www.ncbi.nlm.nih.gov/pubmed/36176758
http://dx.doi.org/10.20517/cdr.2022.37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511796/
https://www.ncbi.nlm.nih.gov/pubmed/36176758
http://dx.doi.org/10.20517/cdr.2022.37

Ejemplares similares